{"id":130009,"date":"2021-08-19T09:00:00","date_gmt":"2021-08-19T09:00:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=2903061"},"modified":"2021-08-19T09:00:00","modified_gmt":"2021-08-19T09:00:00","slug":"al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/","title":{"rendered":"AL Amyloidosis Clinical and Non-Clinical Activities, Emerging Therapies, and Treatment Algorithm | Key Companies in the Therapeutics Domain Includes Sorrento, Caelum Biosciences, Takeda Oncology, Oncopeptides, and others."},"content":{"rendered":"<p><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"\" loading=\"lazy\" style=\"display: block; margin-bottom: 5px; clear:both;max-width: 100%;\" link_thumbnail=\"\" \/><\/p>\n<p><span style=\"font-weight: 400;\"><img decoding=\"async\" loading=\"lazy\" class=\"aligncenter\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/AL-Amyloidosis-Pipeline-Insights.jpg?1629352311183\" alt=\"AL-Amyloidosis-Pipeline-Insights\" width=\"620\" height=\"325\" \/><\/span><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight\u2019s <\/span><strong>AL Amyloidosis Pipeline Insights<\/strong><span style=\"font-weight: 400;\"> report provides a comprehensive outlook of the pipeline therapies that are in different clinical and preclinical stages of development, their launch, and how the market is expected to transform in the aftermath across the AL Amyloidosis domain.<\/span> <span style=\"font-weight: 400;\">The <\/span><strong>AL Amyloidosis Pipeline Analysis<\/strong><span style=\"font-weight: 400;\"> report offers a 360\u00b0 view of the therapeutics landscape by development stage, product type, route of administration, molecule type, and MOA for AL Amyloidosis emerging therapies. The pipeline report lays down the business opportunities, threats, prospective collaborations, strong competitors, and growth strategies.\u00a0<\/span> <strong>Some of the key highlights from the <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/al-amyloidosis-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>AL Amyloidosis Pipeline<\/strong><\/a><strong> report:<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">The available <\/span><strong>therapeutic options in the AL Amyloidosis<\/strong><span style=\"font-weight: 400;\"> landscape aim to slow the disease progression and not stop the disease to improve survival benefits. However, to overcome these challenges, a few companies are working robustly to identify the cause of disease and developing targeted therapy. Several major AL amyloidosis therapies are expected to enter the market by 2030.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Globally, some of the major companies involved in strengthening the <\/span><a href=\"https:\/\/www.delveinsight.com\/report-store\/al-amyloidosis-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>AL Amyloidosis therapeutic pipeline<\/strong><\/a><span style=\"font-weight: 400;\"> include <\/span><strong>Sorrento Therapeutics, Caelum Biosciences, Takeda Oncology, Oncopeptides,<\/strong><span style=\"font-weight: 400;\"> and others.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Some of the key <\/span><strong>pipeline therapies for AL Amyloidosis<\/strong><span style=\"font-weight: 400;\"> include <\/span><strong>STI-6129, Melphalan flufenamide, CAEL-101, Ixazomib,<\/strong><span style=\"font-weight: 400;\"> and others.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Among different pipeline therapies, <\/span><strong>CAEL-101<\/strong><span style=\"font-weight: 400;\"> is one of the most promising therapies expected to launch in the coming years. In August 2020, <\/span><strong>Caelum Biosciences<\/strong><span style=\"font-weight: 400;\"> initiated a double-blind, randomized, multicenter international Phase 3 study of CAEL-101 combined with the standard of care (SoC) for plasma cell dyscrasia (PCD) versus placebo combined with standard of care PCD treatment in patients with Mayo stage IIIa AL amyloidosis that have not received prior treatment.<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>Bristol-Myers Squibb<\/strong><span style=\"font-weight: 400;\"> is investigating <\/span><strong>elotuzumab<\/strong><span style=\"font-weight: 400;\">, in combination with lenalidomide and dexamethasone, and the therapy is in phase II clinical studies. Elotuzumab (Empliciti) is an IgG1k immuno-stimulatory monoclonal antibody targeting the signaling lymphocytic activation molecule F7 (SLAMF7).<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>Oncopeptides AB<\/strong><span style=\"font-weight: 400;\"> has initiated phase I\/II clinical studies for its drug candidate <\/span><strong>Melflufen (melphalan flufenamide)<\/strong><span style=\"font-weight: 400;\"> for the treatment of AL amyloidosis. Melflufen (melphalan flufenamide) is a first-in-class peptide-drug conjugate (PDC) alkylator that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Request for Sample @ <\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/al-amyloidosis-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>AL Amyloidosis Pipeline Insights and Outlook<\/strong><\/a> <a href=\"https:\/\/www.delveinsight.com\/report-store\/al-amyloidosis-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>AL Amyloidosis Pipeline Analysis<\/strong><\/a><strong>: Drug Profile\u00a0<\/strong><\/p>\n<ul>\n<li>STI-6129<\/li>\n<li>Melphalan flufenamide<\/li>\n<li>CAEL-101<\/li>\n<li>Ixazomib<\/li>\n<li>Elotuzumab<\/li>\n<li>Daratumumab<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Dive deeper to know more @ <\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/al-amyloidosis-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>AL Amyloidosis therapeutics and drugs pipeline<\/strong><\/a> <strong>Some of the <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/al-amyloidosis-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Key Companies in the\u00a0 AL Amyloidosis Therapeutics<\/strong><\/a><strong> Space Includes<\/strong><\/p>\n<ul>\n<li>Sorrento Therapeutics<\/li>\n<li>Caelum Biosciences<\/li>\n<li>Takeda Oncology<\/li>\n<li>Oncopeptides<\/li>\n<li>Bristol-Myers Squibb<\/li>\n<li>Janssen Biotech<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/al-amyloidosis-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>AL Amyloidosis Pipeline Therapeutics Assessment<\/strong><\/a><\/p>\n<ul>\n<li><strong>By Stage<\/strong>\n<ul>\n<li>Discovery<\/li>\n<li>Pre-clinical<\/li>\n<li>Phase I<\/li>\n<li>Phase II<\/li>\n<li>Phase III<\/li>\n<li>Pre-registration<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"font-weight: 400;\"><strong>Product Types:<\/strong>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Monotherapy<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Combination\u00a0<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"font-weight: 400;\"><strong>Molecule Types:\u00a0\u00a0<\/strong>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Gene therapies<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Small molecule<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Vaccines<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Polymers<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Peptides<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Monoclonal antibodies<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"font-weight: 400;\"><strong>Mechanism of Action:<\/strong>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Protease inhibitors\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Immunomodulatory\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Multiple kinase inhibitor<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"font-weight: 400;\"><strong>Route of Administration:<\/strong>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Infusion<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Intradermal<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Intramuscular<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Intranasal<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Intravaginal<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Oral<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Parenteral<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Subcutaneous<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Topical<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><strong>Got queries? Reach out for more information @ <\/strong><a href=\"https:\/\/www.delveinsight.com\/sample-request\/al-amyloidosis-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>AL Amyloidosis Drug Pipeline Assessment<\/strong><\/a><strong>\u00a0<\/strong> <strong>Scope of the Report<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><strong>Coverage: <\/strong><span style=\"font-weight: 400;\">Global<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Key Market Players: <\/span><strong>Sorrento Therapeutics, Caelum Biosciences, Takeda Oncology, Oncopeptides, Bristol-Myers Squibb, Janssen Biotech, and several others<\/strong><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Key Pipeline Therapies: <\/span><strong>STI-6129, Melphalan Flufenamide, CAEL-101, Ixazomib, Elotuzumab, Daratumumab, and many more.\u00a0<\/strong><\/li>\n<\/ul>\n<p><strong>Table of Content\u00a0<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td><span style=\"font-weight: 400;\">1<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Report Introduction<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">2<\/span><\/td>\n<td><span style=\"font-weight: 400;\">AL Amyloidosis\u00a0<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">3<\/span><\/td>\n<td><span style=\"font-weight: 400;\">AL Amyloidosis Current Treatment Patterns<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">4<\/span><\/td>\n<td><span style=\"font-weight: 400;\">AL Amyloidosis &#8211; DelveInsight&#8217;s Analytical Perspective<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">5<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Therapeutic Assessment<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">6<\/span><\/td>\n<td><span style=\"font-weight: 400;\">AL Amyloidosis Late Stage Products (Phase-III)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">7<\/span><\/td>\n<td><span style=\"font-weight: 400;\">AL Amyloidosis Mid Stage Products (Phase-II)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">8<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Early Stage AL Amyloidosis Products (Phase-I)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">9<\/span><\/td>\n<td><span style=\"font-weight: 400;\">AL Amyloidosis Pre-clinical Products and Discovery Stage Products<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">10<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Inactive Products<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">11<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Dormant Products<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">12<\/span><\/td>\n<td><span style=\"font-weight: 400;\">AL Amyloidosis Discontinued Products<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">13<\/span><\/td>\n<td><span style=\"font-weight: 400;\">AL Amyloidosis Product Profiles<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">14<\/span><\/td>\n<td><span style=\"font-weight: 400;\">AL Amyloidosis Key Companies<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">15<\/span><\/td>\n<td><span style=\"font-weight: 400;\">AL Amyloidosis Key Products<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">16<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Dormant and Discontinued Products<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">17<\/span><\/td>\n<td><span style=\"font-weight: 400;\">AL Amyloidosis Unmet Needs<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">18<\/span><\/td>\n<td><span style=\"font-weight: 400;\">AL Amyloidosis Future Perspectives<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">19<\/span><\/td>\n<td><span style=\"font-weight: 400;\">AL Amyloidosis Analyst Review<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">20<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Appendix<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">21<\/span><\/td>\n<td><span style=\"font-weight: 400;\"> Report Methodology<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">Know more of what\u2019s covered in the <\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/al-amyloidosis-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>AL Amyloidosis Pipeline Assessment<\/strong><\/a><span style=\"font-weight: 400;\"> report<\/span> <strong>Key Questions Answered in the AL Amyloidosis Report<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What are the current options for AL Amyloidosis treatment?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">How many companies are developing therapies for the treatment of AL Amyloidosis?\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What are the principal therapies developed by these companies in the industry?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">How many therapies are developed by each company for the treatment of AL Amyloidosis?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">How many AL Amyloidosis emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of AL Amyloidosis?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the AL Amyloidosis market?\u00a0<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Request for a Webex demo @ <\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/al-amyloidosis-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>AL Amyloidosis Drug Pipeline<\/strong><\/a><span style=\"font-weight: 400;\"> and get a walk-through of our report\u00a0<\/span> <strong>Latest Reports<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/al-amyloidosis-market\"><strong>AL Amyloidosis Market Insight<\/strong><\/a> DelveInsight&#8217;s &#8220;AL Amyloidosis Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the AL Amyloidosis market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). <a href=\"https:\/\/www.delveinsight.com\/report-store\/al-amyloidosis-epidemiology-forecast\"><strong>AL Amyloidosis Epidemiology Forecast<\/strong><\/a> <span style=\"font-weight: 400;\">DelveInsight&#8217;s AL Amyloidosis Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of AL Amyloidosis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span> <a href=\"https:\/\/www.delveinsight.com\/report-store\/advanced-wound-care-market\"><strong>Advanced Wound Care Market<\/strong><\/a> <span style=\"font-weight: 400;\">DelveInsight\u2019s \u2018Advanced Wound Care Market Insights, Competitive Landscape, and Market Forecast 2026\u2019 report deliver an in-depth understanding of advanced wound care and the historical and forecasted advanced wound care market trends in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/span> <a href=\"https:\/\/www.delveinsight.com\/report-store\/nocturnal-enuresis-market\"><strong>Nocturnal Enuresis Market<\/strong><\/a> <span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Nocturnal Enuresis Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Nocturnal Enuresis market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span> <a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-immune-deficiency-pid-market\"><strong>Primary Immunodeficiency Market<\/strong><\/a> <span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Primary Immunodeficiency Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Primary Immunodeficiency market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span> <a href=\"https:\/\/www.delveinsight.com\/report-store\/dementia-with-diabetes-market-forecast\"><strong>Dementia with Diabetes Market<\/strong><\/a> <span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Dementia with Diabetes Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Dementia with Diabetes market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span> <a href=\"https:\/\/www.delveinsight.com\/report-store\/corneal-endothelial-dystrophy-market\"><strong>Corneal Endothelial Dystrophy Market<\/strong><\/a> <span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Corneal Endothelial Dystrophy market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span> <strong>Healthcare Blogs By DelveInsight<\/strong><\/p>\n<ul>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/key-companies-in-neurological-disorders-market\">Neurological Disease Therapy Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/biomarkers-in-non-small-cell-lung-cancer-therapy-market\">Non-small Cell Lung Cancer Therapy Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/primary-hyperoxaluria-market\">Primary Hyperoxaluria Market Clinical Trials<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/crohns-disease-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Crohn\u2019s Disease Treatment Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/leading-companies-in-the-musculoskeletal-disorders-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Leading Musculoskeletal Disorders and Key Companies<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/peanut-allergy-market?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Peanut Allergy Therapy Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/transcranial-stimulation-devices-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Key Companies in the Transcranial Stimulation Devices Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/uncomplicated-urinary-tract-infections-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Uncomplicated Urinary Tract Infections Market Size<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/leading-companies-in-autoimmune-diseases-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Autoimmune Diseases Treatment Landscape<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/insulin-delivery-devices-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Insulin Delivery Devices Market Size<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/femtech-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Companies in FemTech Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/skin-cancer-treatment-market-and-key-companies\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Common Types of Skin Cancers<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/cardiac-monitoring-devices-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Key Companies in Cardiac Monitoring Devices Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/jak-inhibitors-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Janus Kinase Inhibitors Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/virtual-clinical-trials?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Virtual Clinical Trials Benefits and Challenges<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Major Depressive Disorder Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/advances-in-diabetes-care-and-management\">Advancements in Diabetes Management and Care<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/technological-innovations-in-healthcare?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Technological Innovation in Healthcare<\/a><\/strong><\/li>\n<\/ul>\n<p><strong>About <\/strong><a href=\"https:\/\/www.delveinsight.com\/?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>DelveInsight<\/strong><\/a> <span style=\"font-weight: 400;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.\u00a0 Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform <\/span><a href=\"https:\/\/www.delveinsight.com\/pharmdelve?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>PharmDelve<\/strong><\/a><span style=\"font-weight: 400;\">.<\/span> <strong>Connect With Us at <\/strong><a href=\"https:\/\/www.linkedin.com\/company\/delveinsight-business-research-llp\/\"><strong>LinkedIn<\/strong><\/a><strong> |<\/strong><a href=\"https:\/\/www.facebook.com\/delveinsightindia\/\"><strong> Facebook<\/strong><\/a><strong> |<\/strong><a href=\"https:\/\/twitter.com\/delve_insight\"><strong> Twitter<\/strong><\/a><\/p>\n<p class=\"tags\">Tags: <a href=\"https:\/\/icrowdnewswire.com\/tag\/al-amyloidosis-market\/\" rel=\"tag\">AL Amyloidosis Market<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/al-amyloidosis\/\" rel=\"tag\">AL Amyloidosis<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/al-amyloidosis-epidemiology\/\" rel=\"tag\">AL Amyloidosis Epidemiology<\/a> <\/p>\n<div><strong>See Campaign: <\/strong><a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.delveinsight.com\/<\/a><br \/><b>Contact Information:<\/b><br \/>Shruti Thakur\u00a0 <a href=\"mailto:info@delveinsight.com\">info@delveinsight.com<\/a>\u00a0 +1(919)321-6187\u00a0<\/p>\n<p><b>Tags:<\/b><br \/><a href=\"https:\/\/icrowdnewswire.com\/category\/reportedtimes\/\" rel=\"category tag\">Reportedtimes<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/menafn\/\" rel=\"category tag\">Menafn<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/ips\/\" rel=\"category tag\">IPS<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/pr-wirein\/\" rel=\"category tag\">PR-Wirein<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/icn-internal-distribution\/\" rel=\"category tag\">iCN Internal Distribution<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/extended-distribution\/\" rel=\"category tag\">Extended Distribution<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/research-newswire\/\" rel=\"category tag\">Research Newswire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/language\/english\/\" rel=\"category tag\">English<\/a><\/p>\n<\/div>\n<div>\n<h3>Contact Information:<\/h3>\n<p>Shruti Thakur\u00a0<br \/> <a href=\"mailto:info@delveinsight.com\">info@delveinsight.com<\/a>\u00a0 <br \/> +1(919)321-6187\u00a0<\/p>\n<\/p>\n<\/div>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/\">AL Amyloidosis Clinical and Non-Clinical Activities, Emerging Therapies, and Treatment Algorithm | Key Companies in the Therapeutics Domain Includes Sorrento, Caelum Biosciences, Takeda Oncology, Oncopeptides, and others.<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\">Financial Market Brief<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s AL Amyloidosis Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and preclinical stages of development, their launch, and how the market is expected to transform in the aftermath across the AL Amyloidosis domain. The AL Amyloidosis Pipeline Analysis report offers a 360&deg; view of the therapeutics [&hellip;]<\/p>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/\">AL Amyloidosis Clinical and Non-Clinical Activities, Emerging Therapies, and Treatment Algorithm | Key Companies in the Therapeutics Domain Includes Sorrento, Caelum Biosciences, Takeda Oncology, Oncopeptides, and others.<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/\">Financial Market Brief<\/a>.<\/p>\n<p> <a href=\"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/\" class=\"more-link\">Continue Reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":291,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-130009","post","type-post","status-publish","format-standard","hentry","category-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AL Amyloidosis Clinical and Non-Clinical Activities, Emerging Therapies, and Treatment Algorithm | Key Companies in the Therapeutics Domain Includes Sorrento, Caelum Biosciences, Takeda Oncology, Oncopeptides, and others. - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AL Amyloidosis Clinical and Non-Clinical Activities, Emerging Therapies, and Treatment Algorithm | Key Companies in the Therapeutics Domain Includes Sorrento, Caelum Biosciences, Takeda Oncology, Oncopeptides, and others. - Business\" \/>\n<meta property=\"og:description\" content=\"DelveInsight&rsquo;s AL Amyloidosis Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and preclinical stages of development, their launch, and how the market is expected to transform in the aftermath across the AL Amyloidosis domain. The AL Amyloidosis Pipeline Analysis report offers a 360&deg; view of the therapeutics [&hellip;] The post AL Amyloidosis Clinical and Non-Clinical Activities, Emerging Therapies, and Treatment Algorithm | Key Companies in the Therapeutics Domain Includes Sorrento, Caelum Biosciences, Takeda Oncology, Oncopeptides, and others. appeared first on Financial Market Brief. Continue Reading &rarr;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-19T09:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\" \/>\n<meta name=\"author\" content=\"iCrowdNewswire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"iCrowdNewswire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/\",\"url\":\"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/\",\"name\":\"AL Amyloidosis Clinical and Non-Clinical Activities, Emerging Therapies, and Treatment Algorithm | Key Companies in the Therapeutics Domain Includes Sorrento, Caelum Biosciences, Takeda Oncology, Oncopeptides, and others. - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\",\"datePublished\":\"2021-08-19T09:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\"},\"breadcrumb\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/#primaryimage\",\"url\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\",\"contentUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AL Amyloidosis Clinical and Non-Clinical Activities, Emerging Therapies, and Treatment Algorithm | Key Companies in the Therapeutics Domain Includes Sorrento, Caelum Biosciences, Takeda Oncology, Oncopeptides, and others.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\",\"name\":\"iCrowdNewswire\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"caption\":\"iCrowdNewswire\"},\"sameAs\":[\"https:\/\/heymuse.com\/ips\"],\"url\":\"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AL Amyloidosis Clinical and Non-Clinical Activities, Emerging Therapies, and Treatment Algorithm | Key Companies in the Therapeutics Domain Includes Sorrento, Caelum Biosciences, Takeda Oncology, Oncopeptides, and others. - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/","og_locale":"en_US","og_type":"article","og_title":"AL Amyloidosis Clinical and Non-Clinical Activities, Emerging Therapies, and Treatment Algorithm | Key Companies in the Therapeutics Domain Includes Sorrento, Caelum Biosciences, Takeda Oncology, Oncopeptides, and others. - Business","og_description":"DelveInsight&rsquo;s AL Amyloidosis Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and preclinical stages of development, their launch, and how the market is expected to transform in the aftermath across the AL Amyloidosis domain. The AL Amyloidosis Pipeline Analysis report offers a 360&deg; view of the therapeutics [&hellip;] The post AL Amyloidosis Clinical and Non-Clinical Activities, Emerging Therapies, and Treatment Algorithm | Key Companies in the Therapeutics Domain Includes Sorrento, Caelum Biosciences, Takeda Oncology, Oncopeptides, and others. appeared first on Financial Market Brief. Continue Reading &rarr;","og_url":"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/","og_site_name":"Business","article_published_time":"2021-08-19T09:00:00+00:00","og_image":[{"url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","type":"","width":"","height":""}],"author":"iCrowdNewswire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"iCrowdNewswire","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/","url":"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/","name":"AL Amyloidosis Clinical and Non-Clinical Activities, Emerging Therapies, and Treatment Algorithm | Key Companies in the Therapeutics Domain Includes Sorrento, Caelum Biosciences, Takeda Oncology, Oncopeptides, and others. - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/#primaryimage"},"image":{"@id":"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/#primaryimage"},"thumbnailUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","datePublished":"2021-08-19T09:00:00+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee"},"breadcrumb":{"@id":"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/#primaryimage","url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","contentUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png"},{"@type":"BreadcrumbList","@id":"https:\/\/ipsnews.net\/business\/2021\/08\/19\/al-amyloidosis-clinical-and-non-clinical-activities-emerging-therapies-and-treatment-algorithm-key-companies-in-the-therapeutics-domain-includes-sorrento-caelum-biosciences-takeda-oncology-onco\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"AL Amyloidosis Clinical and Non-Clinical Activities, Emerging Therapies, and Treatment Algorithm | Key Companies in the Therapeutics Domain Includes Sorrento, Caelum Biosciences, Takeda Oncology, Oncopeptides, and others."}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee","name":"iCrowdNewswire","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","caption":"iCrowdNewswire"},"sameAs":["https:\/\/heymuse.com\/ips"],"url":"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/130009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/291"}],"replies":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=130009"}],"version-history":[{"count":1,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/130009\/revisions"}],"predecessor-version":[{"id":130010,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/130009\/revisions\/130010"}],"wp:attachment":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=130009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=130009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=130009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}